Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +46.82%
#2 Purr Purr +35.45%
#3 Pons Pons +35.34%
#4 TENDIES TENDIES +31.66%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.83%
#6 Starpower Starpower +28.19%
#7 StonkBroker StonkBroker +25.85%
#8 SkyAI SkyAI +24.57%
#9 PondCoin PondCoin +21.91%
#10 Magma Finance Magma Finance +20.37%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Settings
Language
ENGLISH
Currency
USD
Theme
InDex Pharmaceuticals Holding AB (publ) InDex Pharmaceuticals Holding AB (publ)

InDex Pharmaceuticals Holding AB (publ)

INDEX
Rank in Stocks #28996
InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to... InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to developing therapeutic solutions for patients affected by ulcerative colitis. The company's flagship drug candidate, Cobitolimod, is presently in Phase III clinical trials, targeting the treatment of moderate to severe ulcerative colitis. Furthermore, InDex is progressing a pipeline of other DNA-based immunomodulatory sequences, which are in the preclinical phase, designed to address various immunological conditions. This enterprise was established in 2000 and operates from its headquarters in Solna, Sweden.
Share Price
$0.04406501
Last synced: 2024-07-09
Market Cap
$23.47M
Change (1 day)
-0.48%
Change (1 year)
0.00%
Country
SE
Trade InDex Pharmaceuticals Holding AB (publ) (INDEX)

Category

Healthcare
Revenue for InDex Pharmaceuticals Holding AB (publ) (INDEX)
Revenue in Aug 2026 TTM: 0
According to InDex Pharmaceuticals Holding AB (publ) latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for InDex Pharmaceuticals Holding AB (publ) from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH